U.S. CDC backs use of redesigned Omicron COVID boostersR&D, TherapeuticsThe U.S. Centers for Disease Control and Prevention (CDC) on Thursday recommended the use of redesigned COVID-19 booster shots for people aged 12 years and older to target the BA.4 and BA.5 Omicron subvariants of the coronavirus. Read more September 1, 2022/by Reuters Health https://www.pharmalive.com/wp-content/uploads/2022/01/Omicron-subtype-has-apparent-transmission-advantage-–-UKHSA-Reuters-1-28-22.jpg 126 240 Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Reuters Health2022-09-01 20:30:032022-09-02 10:41:39U.S. CDC backs use of redesigned Omicron COVID boosters
